Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 10/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485825 | 0.83 | CACNA1B (0.55) | HTR2CCACNA1BNR1I2CYP3A4 | |
| SCHEMBL3485485 | 0.83 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR6CYP3A4 | |
| SCHEMBL3486045 | 0.83 | HTR2C (0.51) | HTR2CHTR2AHTR6CACNA1BSLC6A2 | |
| SCHEMBL3561054 | 0.82 | HTR2C (0.46) | HTR2CHTR2AHTR2BHTR6SLC6A2 | |
| SCHEMBL532533 | 0.82 | KDM4E (0.46) | HTR2CHTR2AHTR6SLC6A2SLC6A3 | |
| SCHEMBL4278784 | 0.79 | CACNA1B (0.45) | HTR6CACNA1BSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12184749 | 0.76 | HTR2C (0.51) | HTR2CHTR2AHTR2BHTR6 | |
| Hydrochloric Acid SCHEMBL20524629 | 0.75 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR6 | |
| SCHEMBL231306 | 0.73 | HTR2A (0.46) | HTR2CHTR2AHTR6CYP3A4SLC6A2 | |
| SCHEMBL17942305 | 0.72 | HTR6 (0.50) | HTR2CHTR2AHTR2BHTR6CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791264-B2 | Benzenesulfonamide compounds and their use as blockers of calcium channels | PURDUE PHARMA L.P. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | PURDUE PHARMA L.P. (CT) | 2010-01-28 | — | — | US | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022595-A1 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels | CACNA1A, CACNA1E, CACNA1B | HTR2C 431/4885HTR2A 499/4885HTR2B 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.